Outcomes of peripheral vasculopathy, such as Raynaud’s phenomenon, were noticed in postmarketing reports and at the therapeutic dosages of CNS stimulants in all age groups all through the program of treatment. Symptoms and signs or symptoms frequently enhanced right after dosage reduction or d